We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Goldshield Grp | LSE:GSD | London | Ordinary Share | GB0002893823 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 486.25 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
10/3/2003 09:34 | Don't forget they made around 20p eps in H1. If H2 is 50% down, p/e will still be about 4. The key to this share is next year's outlook. | njp | |
10/3/2003 07:32 | P/W as inticapted. This company is in serious trouble. 'The Board still expects sales in the six months ending 31 March, 2003 to be in line with expectations, demonstrating good year on year growth in difficult market conditions. However, the Company has experienced higher than anticipated costs as a consequence of which, earnings in the year ending 31 March, 2003 will fall slightly below the Company's expectations.' | matthewa | |
10/3/2003 07:32 | P/W as inticapted. This company is in serious trouble. 'The Board still expects sales in the six months ending 31 March, 2003 to be in line with expectations, demonstrating good year on year growth in difficult market conditions. However, the Company has experienced higher than anticipated costs as a consequence of which, earnings in the year ending 31 March, 2003 will fall slightly below the Company's expectations.' | matthewa | |
20/1/2003 21:45 | I think they will benefit from the forthcoming shake up of the pharmaceutical industry. | ddahj | |
11/1/2003 02:11 | agreed - definitely one to watch but I don't think there is any hurry to rush in and neither does anyone else judging by the way the price is going. | hosede | |
27/12/2002 18:27 | Happy to wait and watch for the moment having baled out on results. The fall looks greatly overdone IMO as the NHS claim looked to be in the price at £3. Would be nice to know exactly how much the NHS are claiming. If it's mostly unfair profits, remember that the company claims to have made only £6.9m of sales of Warfarin over the period in question. Given the first half performance of 22p eps pre exceptionals and goodwill amortisation GSD looks a bargain, but it's firmly out of favour at the moment. | njp | |
24/12/2002 01:54 | This is a difficult one. I am a big personal admirer of Patel & have averaged out at this level 220. I don`t believe the company has lied & if that is the case long term there will be rebound. This is why: Drop in co value far exceeds direct cost of proportion of the 28 mllion. Price already had factored in risk Large family stake. Incredibly well managed and diversified Exceptionally loyal s/holder base(remarkably few sales despite news) Young but experiencd team Loads of admin shifted to low cost base in India. Direct sales customers immune to this news. Multi National. Cons: Executive focus distracted (but well delegated so I don`t believe that is a big concern) Market sentiment. DYOR but IMO will survive and prosper | gelp | |
23/12/2002 14:55 | I am not sure that it is a buy even at this price for a number of reasons including :- * Litigation is very time consuming for top management, * TV selling is no guarantee of sales and can impinge negatively on regular stockits willingness to carry the products - however imo should improve conumer offtake. * Problems with the EU decision on glucosamine from China has hit the company hard and might take longer to bed in new suppliers that estimated. * The supply problems with Antigen All in all I think I would need to see more evidence that these problems had all been overcome before taking a purchase decision - but dyor etc. | pugugly | |
23/12/2002 13:21 | Ouch! but the fall isn't warranted - GSD is sound and will prove this to be a storm in a teacup: but it is a damn nuisance! GSD are a buy. (mitzis - posting that AFTER the RNS is hardly helpful!) Kind regards SAMUEL 1 | samuel 1 | |
23/12/2002 08:52 | I have downgraded today to sell... | mitzis | |
02/12/2002 17:31 | NJP - as you know from my comments this afternoon on the FER board, I am staying with GSD as I think that growth will accelerate even further in the next half because the factors which kept the results rosy rather than very rosy this half, have been dealt with/resolved and there are strong reasons to expect upward movement over next few months.(I would hope for and expect a strong current trading statement in the near future). Kind regards SAMUEL 1 | samuel 1 | |
02/12/2002 16:35 | Exited first thing this morning at 380p as the results weren't as rosy as expected. Still, growth reported despite a number of adverse issues. I see West LB has downgraded to 'neutral' but still have a price target of 460p (was 750p!). Still watching though as may re-enter after the mark down. | njp | |
26/11/2002 00:06 | NJP- just had another good look at the last results and feel more convinced than ever that GSD is likely to hit all the right notes next week. GSD has delivered year after year and the Executive Chairman's June 2002 results statement closing paragraph is as strong a hint of good news as you are likely to find .. "The fundamentals of the Group's business including its clear direction, strengthened management team and operational infrastructure, broadening geographic base, significantly better opportunities for growth in both Europe and US, broader product development portfolio, strong balance sheet and cash flow mean that the Group is better placed than at any time in the Group's history." Time for GSD to have a good hike in its rating IMO. Kind regards SAMUEL 1 | samuel 1 | |
25/11/2002 13:52 | Sam Yes, they seem quite confident, don't they. As for later news, they seem confident that the NHS investigation is a non issue. As for Antigen, I understand they bought the marketing side, with the manufacturing side bought by a Canadian firm, Miza. The latter transaction seems to have gone belly up, so Goldshield may well have to pick it up out of administration to continue supply. Whilst Antigen looks a bit of a mess, it really is small beer compared with the rest of the group, so I can't see it impacting to any great extent on revenues. Both these 'fears' seem well overdone to me, so GSD looks good for 500p plus come results. | njp | |
23/11/2002 00:25 | Sam1 Welcome. Flattery will get you everywhere! Need to get through those two prior tops at 412.5 before we head for £5. Hopefully they won't offer too much resistance as we have the promise of results to drive us this time. The NHS issue is a bit of a blight but certainly I'd agree with you on 550-600p if results deliver and the NHS investigation fears can be seen as irrelevant, as the company claim. | njp | |
23/11/2002 00:12 | I am in this one NJP - always know that I'm in good company when such an erudite accountant as yourself is around a share! Yes, totally agree that the NHS debacle will prove to be storm in a teacup as far as GSD concerned. And the driving force is likely to be excellent results - which should cause GSD to be re-rated: not expensive at £5.50-£6.00 IMO. Kind regards SAMUEL 1 | samuel 1 | |
22/11/2002 11:20 | Anyone into GSD? Moving up prior to results and still v cheap. Looks like fears of the NHS pricing investigation are overdone. | njp | |
22/11/2002 11:07 | Moving up nicely pre results on very little volume. With forecasts of eps inexcess of 50p this year, GSD looks extremely cheap. Marked down due to NHS investigations into profiteering earlier this year, which company claims is misplaced. Still plenty of room for upside. | njp | |
30/10/2002 08:38 | Shares down 9% already today and no shares traded - good one that. | liveinhope | |
11/6/2002 14:24 | robcol thx Looks as though the mkt is giving the benefit of the doubt today with no big selling. I missed getting filled at 370 to go long to play a bounce to 400 ish b4 the selling set in. Being cautious I didn't really want to chase it, but it looks as if its just another one that got away! | byrdsong | |
11/6/2002 13:45 | BS You've probably already picked this up from the report but i thought i'd put it on the board anyway. Taken from the prelims:- "The Group does not believe that the aspect of the SFO investigation which relates to penicillin based products applies to the Group. This is because the Group did not sell any penicillin based products during the period under investigation. So far as concerns that aspect of the SFO investigation which relates to warfarin, the Group believes that this has only very limited application to the Group. The Group had total sales of £6.9 million derived from warfarin during the period under investigation. This equates to 3.7% of the Group's turnover during this period. However, of this £6.9 million, £4.8 million was generated from sales of Marevan, Goldshield's branded version of warfarin. Throughout the period to which the investigation relates, Marevan was sold at prices determined with the Department of Health ('DOH') under the Prescription Pricing Regulation Scheme ('PPRS'). The effect of the PPRS is to prevent the NHS from buying at prices above the PPRS specified levels. Whilst suppliers are free to discount PPRS prices, the Group cannot see that selling at PPRS prices can be considered fraudulent behaviour. The remaining £2.1 million of warfarin sales were derived by the Group during the period April 2000 to 31 December 2000 from the Group's generic warfarin product. Sales of this generic warfarin product during the period under investigation were made, on average, at prices 50% below the applicable Drug Tariff published every month by the DOH. The Directors believe that they have at all times conducted the affairs of the Group in accordance with the highest standards of business probity and will continue to do so. As of June 10, 2002 we have had no further communications from the SFO since their visit." | robcol | |
11/6/2002 09:59 | good results as expected, but any news on the investigation? Almost longed, but reluctant in the face of silence from the company. | byrdsong | |
22/4/2002 23:08 | lodger do u mind indicating where u got out and volume so i can get a clear idea of the position minus your trades? thx | byrdsong | |
22/4/2002 14:10 | B - the three 2000 trades at 10.50 were mine. IG first for tax reasons. | lodger |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions